Shortening the Short Course of Tuberculosis Treatment

N Engl J Med. 2021 May 6;384(18):1764-1765. doi: 10.1056/NEJMe2104499.

Authors

Eric J Rubin¹, Valerie Mizrahi¹

Affiliation

¹ From the Institute of Infectious Disease and Molecular Medicine and the Department of Pathology, Wellcome Centre for Infectious Diseases Research in Africa, and the South African Medical Research Council, National Health Laboratory Service, University of Cape Town Molecular Mycobacteriology Research Unit, University of Cape Town, Cape Town, South Africa (V.M.).

PMID: 33951367
DOI: 10.1056/NEJMe2104499

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Moxifloxacin
Rifampin* / analogs & derivatives
Rifampin* / therapeutic use
Tuberculosis* / drug therapy

Substances

Moxifloxacin
Rifampin
rifapentine